Clinical Evaluation of Everolimus (a Rapamycin Analog) in Restoring Salivary Gland Function to Patients Treated With Radiotherapy for Head and Neck Cancer
Phase of Trial: Phase 0
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary)
- Indications Chemotherapy-induced damage; Salivary gland disorders
- Focus Therapeutic Use
- 27 Nov 2019 Status changed from recruiting to discontinued.
- 17 Jun 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.
- 12 Jul 2018 New trial record